Rossari Biotech Q2 FY27: Revenue 698cr, EBITDA 87cr

Transcript filing under Regulation 30

Rossari Biotech Ltd informed stock exchanges about the transcript of its Q2 and H1 FY27 earnings conference call held on October 19, 2026. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations. The company also referenced its press release for Q2 FY27 results in the same set of updates. Alongside the transcript, the company indicated the availability of the audio recording for the earnings conference call for Q2 and H1 FY27. These disclosures are typically tracked closely because they provide management commentary beyond the headline numbers. The timing matters as the transcript formalises statements made during the call and becomes part of the public record. For investors, this is where details on margins, costs, business mix, and near-term risks are usually clarified.

Record quarter: the headline financials

On the call, management said Rossari Biotech delivered its highest-ever quarterly revenue and EBITDA in Q2 FY27. Revenue from operations for the quarter ended September 30, 2026 stood at INR 697.6 crore, up 19% year-on-year from INR 586.1 crore in Q2 FY26. EBITDA for the quarter was INR 87 crore, up 21% year-on-year, also a record for the company. Profit after tax (PAT) rose to INR 38.9 crore, up 5.5% year-on-year and 11% quarter-on-quarter. Diluted EPS for the quarter was reported at 7.02. Management described the growth as broad-based, with all three business divisions contributing. The company also said it concluded the first half of FY27 on a strong note.

Margins: gross and EBITDA performance

Rossari Biotech reported a gross margin of 31.6% in Q2 FY27. The company said the gross margin was in line with Q2 FY26 and around 200 basis points higher than the 29.6% reported in Q1 FY27. Gross profit for Q2 FY27 was INR 220.3 crore, up 19% year-on-year, and up 6.7% quarter-on-quarter. EBITDA margin for Q2 FY27 stood at 12.5%, compared with 12.3% in Q2 FY26 and 11.6% in Q1 FY27. Management highlighted that margins improved sequentially, while also flagging headwinds from raw material and freight conditions. The company positioned the quarter’s margin profile as an outcome of operating execution amid a volatile external environment.

Costs and investment themes cited by management

On operating costs, the company said employee costs increased 15% year-on-year in Q2 FY27. Other expenses rose 19% year-on-year, which management linked to continued investment in people and expansion initiatives. The call referenced investments in new geographies, the Thailand facility, and a newly set up R&D center. These spending lines were framed as part of scaling the business while expanding capabilities. The company also referred to “headwinds” during the quarter, without changing its record revenue and EBITDA narrative. For investors, the key takeaway was that Rossari delivered higher revenues while continuing to spend on expansion and capability building.

Segment and mix: core B2B, institutional and B2C

The transcript included additional business-mix detail. Management said the company’s core B2B business delivered revenue of INR 619.9 crore in Q2 FY27, a 21% year-on-year increase. Core B2B EBITDA was stated at INR 87.2 crore, up 15% year-on-year, with an EBITDA margin of 14.1% versus 14.8% in Q2 FY26 and 13.5% in Q1 FY27. Management linked the year-on-year margin moderation to the raw material and freight environment and investments to seed newer businesses and geographies. The company’s institutional and B2C business reported revenue of INR 77.7 crore in Q2 FY27, up 3% year-on-year, with management adding that profitability improved significantly.

HPPC division numbers disclosed

Management also shared numbers for the HPPC division. HPPC revenue rose 18% year-on-year to INR 541.9 crore in Q2 FY27. For H1 FY27, HPPC revenue was reported at INR 1,095.1 crore, up 20%. These figures were cited as part of the broader statement that growth was broad-based across divisions. While the transcript excerpt does not list the other divisions’ exact revenues, management’s emphasis was on the fact that the overall record quarter was not driven by a single line item.

H1 FY27 snapshot: profitability and cash generation

Beyond the quarterly numbers, the provided dataset included select first-half metrics. H1 FY27 EBITDA was stated at INR 167 crore. Operating cash flow for H1 FY27 was reported at INR 131 crore. Net debt was stated at INR 221 crore, down from INR 248 crore in June 2026 and INR 281 crore in March 2026. Separately, the dataset also referenced H1 FY27 revenue of INR 1,394.8 crore, described as a 23% year-on-year increase. These data points together indicate a first half marked by growth alongside an improvement in net debt levels.

Revenue estimate miss: what the dataset says

A separate summary in the provided dataset stated that Rossari Biotech “missed revenue estimate” in Q2 FY2026, while also describing revenue of INR 619.9 crore in Q2 FY2027. That summary also referenced a market revenue estimate of INR 692 million equivalent, and said the company missed by 3.61%. The call transcript excerpt, however, clearly presents INR 619.9 crore as core B2B revenue and INR 697.6 crore as total revenue from operations for the quarter. Investors typically reconcile such differences by checking what “revenue” definition is being compared, such as consolidated revenue versus a segment or a specific business scope. The company’s transcript, as disclosed, provides the higher-level consolidated revenue from operations figure for Q2 FY27.

Outlook: management’s growth range for FY27

On the outlook, management said it expects full-year FY27 revenue growth in the mid-teen to high-teen range. The company stopped short of giving precise guidance, citing geopolitical and logistics uncertainty. This is consistent with the commentary about headwinds, even as Rossari posted record quarterly revenue and EBITDA. The emphasis in the transcript was on continuing execution while navigating volatility in input costs and freight. The guidance language suggests management is retaining flexibility rather than committing to a narrow range.

Key numbers at a glance

What to track next

The company’s disclosures point to three near-term items investors are likely to track from subsequent filings and commentary. First is whether the sequential improvement in gross margin and EBITDA margin sustains as raw material and freight conditions evolve. Second is the pace of returns from investments referenced on the call, including the Thailand facility and the newly set up R&D center. Third is how the company refines its FY27 growth commentary given it has indicated a mid-teen to high-teen revenue growth expectation but avoided precise guidance due to uncertainty. The transcript and audio recording disclosures make these points easier to verify and contextualise for the market. Any further updates are expected through regular exchange filings and scheduled investor communications.